|
|
Volumn 17, Issue 4, 2002, Pages 305-
|
|
Ask the expert
|
|
Author keywords
Antibody induction therapy; Basiliximab; Daclizumab; Post transplant focal segmental glomerulosclerosis
|
|
Indexed keywords
BASILIXIMAB;
CYTOKINE;
DACLIZUMAB;
IMMUNOSUPPRESSIVE AGENT;
INTERLEUKIN 2 RECEPTOR;
INTERLEUKIN 2 RECEPTOR ANTIBODY;
INTERLEUKIN 8;
LYMPHOCYTE ANTIBODY;
LYMPHOKINE;
MONOCLONAL ANTIBODY;
THYMOCYTE ANTIBODY;
HYBRID PROTEIN;
IMMUNOGLOBULIN G;
CHILD;
CORRELATION ANALYSIS;
CYTOKINE RELEASE;
FOCAL GLOMERULOSCLEROSIS;
HUMAN;
IMMUNOSUPPRESSIVE TREATMENT;
KIDNEY ALLOGRAFT;
KIDNEY FAILURE;
LYMPHOCYTE ACTIVATION;
MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS;
NOTE;
ONSET AGE;
POSTOPERATIVE COMPLICATION;
PRIORITY JOURNAL;
RECURRENCE RISK;
RISK FACTOR;
T LYMPHOCYTE;
ARTICLE;
IMMUNOTHERAPY;
KIDNEY TRANSPLANTATION;
RECURRENT DISEASE;
ANTIBODIES, MONOCLONAL;
GLOMERULOSCLEROSIS, FOCAL SEGMENTAL;
HUMANS;
IMMUNOGLOBULIN G;
IMMUNOSUPPRESSIVE AGENTS;
IMMUNOTHERAPY;
KIDNEY TRANSPLANTATION;
RECOMBINANT FUSION PROTEINS;
RECURRENCE;
RISK FACTORS;
|
|
EID: 0036951951
PISSN: 0931041X
EISSN: None
Source Type: Journal
DOI: 10.1007/s00467-002-0828-z Document Type: Note |
|
Times cited : (11)
|
|
References (3)
|
